Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
about
Exercise for cancer cachexia in adultsExercise for cancer cachexia in adultsStudy Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)Towards curative therapy in gastric cancer: Faraway, so close!Interactions between muscle stem cells, mesenchymal-derived cells and immune cells in muscle homeostasis, regeneration and diseaseMuscle dysfunction in cancer patientsThe evaluation of body composition: a useful tool for clinical practiceLean tissue imaging: a new era for nutritional assessment and intervention.Body composition changes in females treated for breast cancer: a review of the evidenceGaps in nutritional research among older adults with cancerThe impact of sarcopenia on survival and complications in surgical oncology: A review of the current literatureA comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patientsCancer cachexia: impact, mechanisms and emerging treatmentsLower Pectoralis Muscle Area Is Associated with a Worse Overall Survival in Non-Small Cell Lung CancerAssociation of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective reviewSarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinomaLean body mass: the development and validation of prediction equations in healthy adultsModels of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis.Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancerInflammation based regulation of cancer cachexiaHerbal medicines for cancer cachexia: protocol for a systematic review.Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature.Panoramic ultrasound: a novel and valid tool for monitoring change in muscle massFish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia.Progressive resistance training and cancer testis (PROTRACT) - efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial.Body composition, symptoms, and survival in advanced cancer patients referred to a phase I serviceUnderstanding cancer-induced cachexia: imaging the flame and its fuel.Decreased core muscle size is associated with worse patient survival following esophagectomy for cancer.Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis.Pre-operative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancerThe diversity of nutritional status in cancer: new insightsChanges in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study.The effect of individualized nutritional counseling on muscle mass and treatment outcome in patients with metastatic colorectal cancer undergoing chemotherapy: a randomized controlled trial protocolNegative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal CancerSkeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.Risk factors, complications and survival after upper abdominal surgery: a prospective cohort study.Preserved muscle oxidative metabolic phenotype in newly diagnosed non-small cell lung cancer cachexia.Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol.
P2860
Q24187827-C28256E0-6B64-41D0-8C32-D986811B721AQ24197733-8A39A2C9-BCF7-46E6-8742-0F72A83136ABQ26747940-41B1B8E5-DD14-431E-8D44-7C43E01E45F3Q26778029-CA2BC90B-E4F3-4C0B-AC38-A0580B002D1BQ26800192-6BB260AE-CBF2-4F80-B932-0C0793B95BE8Q26822365-54433C35-9F06-4EB1-B19F-C74F5DEDDB84Q26825173-7F69B488-5F36-43EA-84CA-223E74AB16B3Q26865480-71DD3634-2553-4EC9-9F26-924FE949D773Q27004662-4A01EEB8-0241-4838-B3A6-85CC51F4AFA6Q28067552-F91F2E5F-5326-4062-B5FD-01F7D227843EQ28081125-90107373-BCA8-4932-B21C-9A6510199B1BQ28364947-7FAB675C-6FA4-480B-B5E5-B7EF7D3C9B94Q28384479-E92BB55D-09B2-478B-B371-60FA6664DEFAQ28394473-B777E50F-6B52-4C97-A9FC-335A2EA6B9BEQ28545175-9F72A5DA-CE49-4368-A3B9-9947EA7B48FBQ28729059-59924255-1AD4-4FA8-9933-1D46059372A4Q31150922-CD73203A-C11C-4386-A18B-4243B338572CQ33349016-CA1442FF-B656-401A-B950-0857E811E0F8Q33400294-FB54BF47-8ED1-498C-B642-DE8CA31153ADQ33403870-A2C9B753-8C61-4717-883A-8656419A6EA5Q33589369-38071CF3-625F-4178-9F46-B08CA7DFC2B1Q33615916-97466F93-6F74-4CD1-A3AA-3E5DE700B486Q33744800-98EFCBF7-AFC4-46F4-871C-3428DE578AC7Q33765436-50A0D5AD-1FC4-46E2-AEE3-2D9340EA1391Q33813569-1D7D7032-3946-42C7-92B5-C3506E1D7091Q33880985-C5325C21-4E55-4C2F-8E70-39380D0EC282Q33977589-A9FF6347-8186-4BEF-A003-FBFE608E1496Q34123648-6E2EB69F-4325-4B3E-9B7D-5468D3DCAA09Q34138093-9D04703C-4F8A-47DE-A298-36E129B649B4Q34228955-A84DF7DC-1450-4815-8C9C-DF5E668AA2B5Q35097594-7BCDA308-A04A-4479-8AD8-B744945E1678Q35166583-C6AC32E2-52CA-4081-B87E-16641DC600D2Q35584083-379B04CA-EDC6-473F-9582-11D3D9899BA2Q35584120-143EE319-BA7B-44D1-9721-04089C277AF6Q35605586-4F78B37F-0714-45C0-B79C-D89A0F52F6BCQ35662253-E7F73D8F-415D-4774-BCC6-DF775ECCEA5CQ35674557-AE8D455B-8667-495E-B893-E1C0588B4AE1Q35684454-3A1AEFEC-EDEC-455D-80F0-8EA747713DC9Q35690207-F4232A73-6443-4232-8B32-CDE7C3AEC438Q35708619-BDD8EF99-7992-4CA5-8B2B-24E185171050
P2860
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Sarcopenia as a determinant of ...... eiving capecitabine treatment.
@en
Sarcopenia as a determinant of ...... eiving capecitabine treatment.
@nl
type
label
Sarcopenia as a determinant of ...... eiving capecitabine treatment.
@en
Sarcopenia as a determinant of ...... eiving capecitabine treatment.
@nl
prefLabel
Sarcopenia as a determinant of ...... eiving capecitabine treatment.
@en
Sarcopenia as a determinant of ...... eiving capecitabine treatment.
@nl
P2093
P1476
Sarcopenia as a determinant of ...... eiving capecitabine treatment.
@en
P2093
Carla M M Prado
Edith Pituskin
John R Mackey
Katia Tonkin
Linda J McCargar
Marina Mourtzakis
Michael B Sawyer
Sheryl Koski
Tony Reiman
P304
P356
10.1158/1078-0432.CCR-08-2242
P407
P577
2009-04-07T00:00:00Z